Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy

GlobeNewswire June 12, 2019

Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting

GlobeNewswire June 1, 2019

Mersana Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference

GlobeNewswire May 30, 2019

Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 20, 2019

Mersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Updates

GlobeNewswire May 9, 2019

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates

GlobeNewswire May 2, 2019

New Research: Key Drivers of Growth for Liberty Global, KKR Real Estate Finance Trust, AGCO, Model N, STAAR Surgical, and Mersana Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire April 9, 2019

Mersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire April 1, 2019

Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019

GlobeNewswire March 25, 2019

 Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

GlobeNewswire March 8, 2019

Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference

GlobeNewswire March 6, 2019

Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire March 5, 2019

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates

GlobeNewswire March 1, 2019

Mersana Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire March 1, 2019

Mersana Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire February 28, 2019

Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond

GlobeNewswire January 4, 2019

Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2019

New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire November 28, 2018

Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer

GlobeNewswire November 27, 2018

Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates

GlobeNewswire November 13, 2018